VALBIOTIS
22.2.2021 17:42:09 CET | Business Wire | Press release
Regulatory News:
VALBIOTIS (FR0013254851 – ALVAL / eligible for the PEA/SME) (Paris:ALVAL), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient's First Visit in the Phase II HEART clinical study evaluating TOTUM-070, an innovative active substance for the reduction of blood LDL-cholesterol levels, a risk factor for cardiovascular disease.
The Company is stepping up development of TOTUM-070 in 2021, with the completion of a complementary clinical study and preclinical work on lipid metabolism. These preclinical results will be submitted to the American Heart Association (AHA) meeting at the end of the year.
Murielle CAZAUBIEL, member of the Management Board and Director of Development and Medical Affairs at VALBIOTIS, comments: “The start of recruitment for the Phase II HEART clinical study kicks off a decisive year for the development of TOTUM-070. This study should demonstrate the clinical efficacy of our active substance against excess blood LDL-cholesterol, a major risk factor for cardiovascular disease worldwide. Pending these results in early 2022, and given the potential of TOTUM-070, we have decided to conduct several complementary clinical and preclinical studies simultaneously this year. This is an ambitious program, which should provide a maximum amount of data by early next year and confirm TOTUM-070 as an additional innovation for people at risk of cardiovascular disease.”
The randomized, double-blind, placebo-controlled, multicenter, Phase II HEART clinical study is designed to evaluate the efficacy of a 5g daily dose of TOTUM-070 on blood LDL-cholesterol levels, its primary endpoint. The study will include 120 people with LDL-cholesterol levels between 130 and 190 mg/dL. Results are expected in early 2022.
Development of TOTUM-070 stepped up in 2021
Simultaneously with the HEART study, VALBIOTIS has decided to conduct a complementary clinical study to expand knowledge of TOTUM-070 and its effects on lipid metabolism in humans. Conducted on a limited number of volunteers, it will combine a bioavailability study, metabolomic analysis (characterization and quantification of TOTUM-070 metabolites) and targeted ex-vivo mode of action tests on human cell models, mainly hepatic. Results are expected before the end of 2021.
Finally, a series of preclinical experiments will be launched and completed in 2021. Conducted on the VALBIOTIS R&D platform, this work is intended to detail the impact of TOTUM-070 on lipid metabolism in a predictive model of human pathophysiology. The results will be submitted to the annual meeting of the American Heart Association (AHA), the leading American learned society in the cardiovascular field, to be held from November 13 to 15, 2021.
Once development is complete, TOTUM-070, a new Health Nutrition product, will be positioned for individuals with LDL-hypercholesterolemia, at levels up to 190 mg/dL, with a moderate overall cardiovascular risk. At the end of 2020, the Company provided detailed market data on hypercholesterolemia and the role of TOTUM-070 in its management (see press release of October 27, 2020 ).
ABOUT THE HEART STUDY
The Phase II HEART clinical study is designed to evaluate the efficacy of a 5g daily dose of TOTUM-070 on blood LDL-cholesterol levels, a risk factor for cardiovascular disease, in the absence of lipid-lowering treatment.
This randomized, double-blind, placebo-controlled, multicenter study will include 120 people with untreated moderate hypercholesterolemia and blood LDL-cholesterol levels between 130 and 190 mg/dL. Participants will be divided into 2 equivalent arms of 60 people, supplemented for 6 months with TOTUM-070 or placebo.
The primary endpoint of the study will be the reduction of blood LDL-cholesterol levels, with several metabolic secondary endpoints of interest.
ABOUT TOTUM-070
TOTUM-070 is an innovative active substance derived from food plant extracts, without phytosterols or red rice yeast, developed to act on lipid metabolism in hypercholesterolemic individuals.
Once development is complete, this new Health Nutrition product will be positioned in particular for people with LDL-hypercholesterolemia, at levels up to 190 mg/dL, with a moderate overall cardiovascular risk. TOTUM-070 may be recommended in this large population for whom no first-line drug treatment is currently recommended, with the aim of reducing LDL-cholesterol levels and thus overall cardiovascular risk.
ABOUT VALBIOTIS
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
For more information about VALBIOTIS, please visit: www.valbiotis.com
.
Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150
DISCLAIMER
This press release contains forward-looking statements about VALBIOTIS' objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com
).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005407/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ and Unlimitail Collaborate to Deliver the Next Generation of Omnichannel Retail Media Insights & Measurement Across Retailers and Countries16.6.2026 11:00:00 CEST | Press release
Enabling advertisers to prove ROI across retailers, markets, and channels with interoperable, AI-powered measurement Retail media investment is accelerating globally, with 67% of CMOs planning to increase spending on retail media networks (RMNs) in 2026. Yet only 53% believe today's RMNs provide adequate measurement and attribution capabilities, highlighting a critical gap in proving true business impact across retailers and markets.* Today, NIQ (NYSE: NIQ), a leading consumer intelligence company, and Unlimitail, a leading retail media network, announced a strategic collaboration designed to help brands and retailers unlock a new era of retail media accountability through advanced measurement, consumer insights, interoperable data infrastructure, and AI-powered analytics. This collaboration will combine Unlimitail's extensive retail media network, which spans 21 countries, 35 retailers, more than 120 retailer websites, and over 250 million loyalty cardholders, with NIQ's industry-lead
Thredd Expands Partnership with ID DISTRIBUTION to Power Next Phase of Employee Benefits and Expense Innovation16.6.2026 11:00:00 CEST | Press release
Paris-based fintech will extend its card program into corporate expense management and support continued European expansion Thredd, the AI-first issuer processing platform, today announced an expanded partnership with ID DISTRIBUTIONthrough its flagship program Vaziva, a leading employee benefits and payments platform, to support its growth beyond consumer payments, into corporate payments, as well as their international expansion. Thredd has worked with ID DISTRIBUTIONsince 2020, supporting the company’s consumer offering in France with physical and digital card issuing and payments processing capabilities. Its Vaziva card program enables companies to digitally manage and distribute multiple types of employee benefits through a single prepaid Mastercard-branded card experience. The program supports convenient, secure card usage for employees to access and use benefits across categories including lunch, gifts, culture, holidays, and travel. With more employers seeking simpler, more dig
Eastnets Launches FinCrime Intelligence Platform to Unify Financial Crime Investigations16.6.2026 10:00:00 CEST | Press release
Eastnets, a global provider of compliance and payment solutions, today announced the launch of FinCrime Intelligence Platform (FCIP), a new investigation and orchestration layer that helps financial institutions unify financial crime operations, improve investigator productivity and gain a single view of risk across AML, sanctions, KYC and fraud. As financial crime operations grow in complexity, many institutions struggle with fragmented investigation tools and inconsistent workflows. FCIP addresses this challenge by providing a single, governed workspace for managing cases across compliance domains - without replacing existing detection systems. Eastnets’ FinCrime Intelligence Platform delivers centralised case management across AML, sanctions screening and KYC, structured, multi‑level investigative workflows with assistive, explainable AI to support, and not replace, human decision-making, providing full audit trails and management oversight. By consolidating AML, fraud, KYC, and scr
Respond.io Raises $62.5M Series B to Scale AI-Powered Customer Conversations Into North America and Europe16.6.2026 10:00:00 CEST | Press release
62.5M Series B led by Camber Partners, with existing investors participating. Respond.io is profitable with $35M ARR, 169% year-over-year growth, and a 30% profit margin. New capital will fund expansion into and mergers and acquisitions within North America and Europe. Respond.io, a customer conversation management platform, today announced a $62.5 million Series B round led by Camber Partners, with participation from Endeavor Catalyst and existing investors. What respond.io does Respond.io enables mid-market B2C businesses to grow revenue from high volumes of customer chats and calls. It unifies WhatsApp, Instagram, TikTok, Messenger, LINE, Telegram, WeChat, voice calls, email, web chat and 16 more integrations into a single platform with AI agents, automation, and CRMs. This turns fragmented customer conversations into a measurable revenue engine, purpose-built for real-world scale and complexity. The company serves industries where customers initiate conversations before buying, boo
Optimum Asset Management’s Investor Summit in Portofino brings together Mike Pompeo, Matteo Renzi and leaders across government, finance and industry to discuss the future of the global economy and geopolitics16.6.2026 09:30:00 CEST | Press release
Mike Pompeo addressed geopolitical risks including China, Iran, Ukraine and Europe-US security cooperation. Matteo Renzi, Edoardo Rixi and senior government representatives joined discussions on European competitiveness, infrastructure and energy. The summit convened institutional investors, entrepreneurs and financial market professionals to discuss the future of the global economy. The first edition of the Optimum Investors Summit – The Portofino Conversation, hosted by European real estate private equity investment firm Optimum Asset Management and its Italian partners Alberto Matta, Rodolfo Misitano, Enrico Imbraguglio and Andrea Suriano, concluded with strong participation from institutional investors (including pension funds), entrepreneurs, government representatives and financial market professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615915564/en/ Alberto Matta, Managing Partner at Optimum Asset Mana
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom